[Click eStock] "L&K Bio, Regional Expansion and New Product Launch"

Korea Investment & Securities expected L&K Bio's growth speed to accelerate through regional expansion and new product launches on the 5th.

It was estimated that L&K Bio achieved sales of 36.2 billion KRW and operating profit of 4.4 billion KRW on a consolidated basis last year. This represents an increase of 20.9% and 116.1% respectively compared to the previous year.

Si-on Kang, a researcher at Korea Investment & Securities, explained, "Sales of height-expansion products increased to around 10 billion KRW annually, driving external growth," adding, "The number of surgical cases in the U.S. using ‘PassLock-TM,’ which accounts for 90% of height-expansion sales, is increasing."

He continued, "This year, the growth speed is expected to accelerate through regional expansion and new product launches," and added, "In addition to the main market, the U.S., expansion into Asia, South America, and Europe is underway." He emphasized, "Last year, sales of height-expansion cages began in Vietnam and Indonesia," and "This year, the plan is to expand to countries such as Taiwan and Hong Kong."

Researcher Kang forecasted, "Approval for five types of height-expansion products in Brazil, the largest market in South America, will be completed within the first half of the year," and "The new pectus implant ‘Pectus’ will also contribute to growth."

Sales of 48 billion KRW and operating profit of 9.6 billion KRW are expected this year, representing increases of 32.7% and 118.4% respectively compared to last year.

This content was produced with the assistance of AI translation services.